VolitionRx (VNRX) Competitors

ARCA biopharma (NASDAQ:ABIO) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings.

Does the media refer more to ABIO or VNRX?

In the previous week, ARCA biopharma had 1 more articles in the media than VolitionRx. MarketBeat recorded 3 mentions for ARCA biopharma and 2 mentions for VolitionRx. ARCA biopharma's average media sentiment score of 0.74 beat VolitionRx's score of 0.00 indicating that VolitionRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARCA biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VolitionRx	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in ABIO or VNRX?

56.4% of ARCA biopharma shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 30.9% of ARCA biopharma shares are held by company insiders. Comparatively, 15.4% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is ABIO or VNRX more profitable?

ARCA biopharma has a net margin of 0.00% compared to ARCA biopharma's net margin of -4,557.29%. ARCA biopharma's return on equity of 0.00% beat VolitionRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARCA biopharma	N/A	-13.80%	-13.33%
VolitionRx	-4,557.29%	N/A	-154.24%

Do analysts rate ABIO or VNRX?

VolitionRx has a consensus price target of $2.50, suggesting a potential upside of 305.06%. Given ARCA biopharma's higher possible upside, analysts clearly believe VolitionRx is more favorable than ARCA biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARCA biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
VolitionRx	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor ABIO or VNRX?

ARCA biopharma received 120 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 42.86% of users gave ARCA biopharma an outperform vote while only 33.33% of users gave VolitionRx an outperform vote.

Company	Underperform	Outperform
ARCA biopharma	Outperform Votes 123 42.86%	Underperform Votes 164 57.14%
VolitionRx	Outperform Votes 3 33.33%	Underperform Votes 6 66.67%

Which has more volatility & risk, ABIO or VNRX?

ARCA biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Which has better earnings and valuation, ABIO or VNRX?

ARCA biopharma has higher earnings, but lower revenue than VolitionRx. ARCA biopharma is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARCA biopharma	N/A	N/A	-$5.34M	-$0.37	-8.78
VolitionRx	$770K	65.78	-$35.32M	-$0.51	-1.21

Summary

ARCA biopharma beats VolitionRx on 9 of the 16 factors compared between the two stocks.